mosanna-therapeutics
(2)
Jonathan Talbot and the value of a second look
Before co-founding Mosanna Therapeutics, Jonathan Talbot studied both science and finance. Now the Melodia CEO and 2026 Strüngmann Award winner is building a career around the possibilities that survive a change of plans.
David Weber
David Weber, PhD, is the President and CEO of Mosanna Therapeutics, a Redwood City biotech developing MOS118, a bedtime nasal spray for obstructive sleep apnea that aims to restore the body's natural airway reflex during sleep. A biotech operator with more than 30 years in drug development, capital formation, and corporate strategy, he previously led Otonomy through its IPO and multiple clinical programs, and served as CEO of MacuSight and Oculex Pharmaceuticals. He joined Mosanna in June 2025 as the company launched with an $80 million Series A.